Cellectar Biosciences, Inc.
CLRB- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001279704
No open-market purchases or sales by Cellectar Biosciences, Inc. insiders were filed in the last 90 days; 29 institutions reported holding it in 13F filings for Q2 2026, worth $9.08M in total; no superinvestor holds it.
Q2 2026 vs. Q1 2026
How the institutions holding Cellectar Biosciences, Inc. changed between Q1 2026 and Q2 2026.
All holders in Q2 2026All holders in Q1 2026
| Measure | Q1 2026 | Q2 2026 | Change |
|---|---|---|---|
| Holders | 19 | 29 | +10 |
| Shares | 310.7K | 3.26M | +2.95M (+949.1%) |
| Value | $812.9K | $9.08M | +$8.27M (+1,017.0%) |
New holders (14)
Institutions that held Cellectar Biosciences, Inc. at the end of Q2 2026 but not at the end of Q1 2026.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Caligan Partners LP | 469,998 | $1.31M | 0.06% |
| StemPoint Capital LP | 354,938 | $986.7K | 0.17% |
| Silverarc Capital Management, LLC | 321,728 | $894.4K | 0.10% |
| Jupiter Topco LLC | 274,156 | $759.4K | 0.00% |
| Balyasny Asset Management LLC | 220,000 | $611.6K | 0.00% |
| Nantahala Capital Management, LLC | 219,998 | $611.6K | 0.04% |
| Empery Asset Management, LP | 189,605 | $527.1K | 0.61% |
| Diadema Partners LP | 138,341 | $384.6K | 0.14% |
| Stonepine Capital Management, LLC | 104,550 | $290.6K | 0.22% |
| Persistent Asset Partners Ltd | 92,983 | $258.5K | 0.08% |
| Boothbay Fund Management, LLC | 85,069 | $236.5K | 0.00% |
| Acadian Asset Management LLC | 16,577 | $46.0K | 0.00% |
| Northern Trust Corp | 14,839 | $41.3K | 0.00% |
| Barclays PLC | 561 | $1.56K | 0.00% |
Sold out (4)
Institutions that held Cellectar Biosciences, Inc. at the end of Q1 2026 and filed for Q2 2026 without it.
| Institution | Shares, Q1 2026 | Value, Q1 2026 |
|---|---|---|
| Warberg Asset Management LLC | 13,900 | $35.3K |
| Tower Research Capital LLC (TRC) | 793 | $2.01K |
| Vanguard Global Advisers, LLC | 563 | $1.43K |
| FMR LLC | 10 | $25 |